What Imactiv-3D does

Imactiv-3D SAS is a French preclinical imaging services company founded in 2015 in Toulouse by Jean-Michel Lagarde, a Pierre Fabre-trained optics and image analysis engineer. The company delivers 2D and 3D imaging and quantitative image analysis to pharmaceutical, biotech, cosmetics, and academic research clients engaged in preclinical studies. The business operates as a privately held SAS with a core team of four members (CEO, scientific advisor, image processing project manager, biology and imaging project manager) and is headquartered at Centre Pierre Potier in Toulouse.

The technical platform rests on two complementary modalities: 2D Whole Slide Imaging (WSI) using a VS200 Evident scanner with six objectives (2x–60x immersion) and multiple contrast modes, and 3D Light-Sheet Fluorescence Microscopy (LSFM) supporting volumetric imaging of whole organs at subcellular resolution with multi-channel acquisition. Service modules are organized by application domain — skin, adipose tissue, vascularization, brain, cardiac, obesity/metabolism, and 3D cell models — and combine acquisition with proprietary image processing pipelines (atlas-based brain quantification, vascular skeletonization, label-free elastin fiber analysis, automatic adipocyte detection). Carl Zeiss SAS is a core technology partner providing LSFM and WSI platforms.

Revenue is generated through project-based professional services contracts priced per quote, with a sales-led B2B go-to-market. Engagement is co-designed with clients through a dedicated interlocutor and framing workshops, and deliverables include quantitative metrics, publication-ready figures, and documented datasets. The company markets itself primarily through scientific publications, webinars, LinkedIn, and direct contact, with no disclosed funding, institutional investors, or public revenue figures.

Name

Imactiv-3D

Legal name

Imactiv-3D SAS

Website

https://imactiv-3d.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Imactiv-3D is a French preclinical imaging services company combining 2D whole slide imaging and 3D light-sheet fluorescence microscopy with biology and image analysis expertise to serve pharmaceutical, cosmetics, and academic research clients.

Ownership category

akta.pro rank

Product category

Preclinical Imaging Services

NAICS

Scientific Research and Development Services (5417), Diagnostic Imaging Centers (621512)

SIC

Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)

Keywords

• Preclinical imaging services
• Light-sheet fluorescence microscopy
• Whole slide imaging
• Quantitative image analysis
• 3D histology

Headquarters

HQ city

Toulouse

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Preclinical Imaging Services: Project-based professional services providing 2D and 3D imaging, image analysis, and quantitative metrics for preclinical research. Revenue generated through service contracts for specific studies or imaging projects.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Imactiv-3D provides project-based preclinical 2D and 3D imaging services combined with experimental biology expertise and quantitative image processing. Its core platforms are Whole Slide Imaging (WSI) for high-throughput histology and Light-Sheet Fluorescence Microscopy (LSFM) for whole-organ 3D volumetric imaging, with service modules across skin, adipose, vascular, brain, cardiac, obesity/metabolic, and 3D cell model applications delivered as custom engagements to pharmaceutical, cosmetics, and academic research clients.

Product overview

Imactiv-3D provides preclinical imaging services organized around two core technology platforms: 2D Whole Slide Imaging (WSI) using VS200 Evident scanner for high-throughput histological analysis, and 3D Light-Sheet Fluorescence Microscopy (LSFM) for volumetric organ-level imaging. Service modules cover seven application domains (skin, adipose tissue, vascularization, brain, heart, obesity/metabolism, 3D cell models) with specialized sub-services for fiber analysis, lipid quantification, and atlas-based brain quantification. The portfolio combines 2D/3D imaging modalities with quantitative image analysis, segmentation, and publication-ready deliverables for pharmaceutical, cosmetics, and academic research clients.

Differentiator

Problem solved

Functional benefit

Products and services

• 2D Imaging / Histology (WSI) High-resolution whole slide imaging (WSI) digitization service for histological samples using a VS200 Evident scanner with 6 objectives (2x, 4x, 10x, 20x, 40x, 60x immersion), 180-slide capacity, and support for brightfield, polarized light, fluorescence, darkfield, and phase contrast modalities. Delivered with automated quantitative analysis using validated algorithms adapted to research endpoints, and intended for pharmaceutical, biotech, cosmetics, and academic research clients.
• 3D Imaging (LSFM) Light-sheet fluorescence microscopy (LSFM) service for 3D volumetric imaging of entire organs and tissues with subcellular resolution, supporting multi-channel simultaneous acquisition on volumes up to several cm³. Includes advanced 3D analysis such as segmentation, volumetric quantification, spatial analysis, and atlas registration for brain studies, aimed at preclinical research in pharma, biotech, cosmetics, and academia.
• Skin Imaging Services Skin and cutaneous tissue imaging and analysis service combining 2D histology (WSI) for rapid cellular quantification and 3D LSFM for intact tissue visualization, including 3D fiber network analysis (orientation, density, structure) for dermatological and dermocosmetic research.
• Adipose Tissue Imaging Quantitative analysis of adipocytes and adipose tissue environment using combined 2D/3D imaging and lipid quantification, including adipocyte size analysis, lipid droplet quantification, differentiation studies, and microenvironment analysis covering vascular and connective tissue structures.
• 3D Vascularization Imaging 3D vascular and lymphatic network analysis service for preclinical studies, covering blood vessel characterization (density, diameter, branching, terminations), lymphatic vessel mapping, microcirculation analysis, and anti-angiogenic treatment evaluation across multiple organ types.
• Brain 3D Imaging Whole-brain LSFM imaging service with atlas registration for standardized quantification, including c-Fos activation analysis, target engagement studies, CNS biodistribution studies, and regional brain quantification using atlas/ROI-based analysis for neuroscience and CNS drug discovery research.
• Cardiac 3D Imaging Whole-heart 3D imaging service covering fibrosis quantification (post-infarction, angiotensin treatment), coronary vascular network analysis (density, length, volume, organization), and ventricular volume measurements for cardiovascular preclinical research and drug efficacy validation.
• Obesity / Metabolic Studies 3D metabolic indicators service for obesity research, including organ-level phenotyping (volumes, spatial distributions, intra-organ heterogeneity), vascular/lymphatic/innervation network analysis (density, length, tortuosity, branching, connectivity), and adipose tissue architecture studies.
• 3D Cell Models Imaging 3D imaging analysis service for spheroid and organoid models, including in-toto immunostaining, antibody/sonda diffusion and penetration profiling, advanced phenotyping with multiplexing and co-staining, and morphometric organization analysis (size, circularity, necrosis, internal structures).
• 3D Fiber Analysis Label-free 3D elastin fiber network analysis service using LSFM endogenous signal, providing quantitative metrics including useful volume, fiber volume density, total fiber length, linear density, and comparisons between conditions for anti-aging, photo-aging, firmness, and tissue repair research.
• Lipid Analysis Quantitative lipid analysis service for obesity and adipose tissue metabolism research, measuring lipid droplet surface, mean diameter, droplet count per cell, differentiation percentage (Bodipy/DAPI colocalization), heterogeneity and size distribution, with optional fibro-inflammation analysis (collagen/fibronectin segmentation).

Quantifiable outcome

• Approximately 30,000 adipocytes quantified per slide
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• DIVA ExpertiseminorStrategic or Co-development PartnerFeatured partner logo on website indicating collaborative relationship in imaging expertise.
• INSERMminorStrategic or Co-development PartnerFeatured partner logo indicating research collaboration and scientific expertise exchange.
• Université Paul SabatierminorStrategic or Co-development PartnerAcademic partner from Toulouse region, indicating research collaboration.
• CNRSminorStrategic or Co-development PartnerFeatured partner logo indicating scientific research collaboration.
• Carl Zeiss SAScoreTechnology or IntegrationEquipment partner providing LSFM and WSI imaging technology platforms. Zeiss is featured prominently as technology provider.
• Toulouse MetropoleminorStrategic or Co-development PartnerRegional metropolitan support indicating local ecosystem integration.
• EurobiomedminorStrategic or Co-development PartnerHealth-tech cluster member providing networking and business development support.
• AFSSIminorStrategic or Co-development PartnerAssociation member for scientific imaging and innovation collaboration.
• PhysiogenexminorStrategic or Co-development PartnerFeatured partner in preclinical pharmacology services.
• IMLINFOminorStrategic or Co-development PartnerPartner logo indicating imaging and information technology collaboration.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Others

• 3DHISTECH: Digital pathology and WSI scanner manufacturer with service offerings. Comparable as a WSI instrumentation and digital pathology ecosystem player serving histology labs and CROs.

Emerging players

• Indica Labs: Digital pathology AI software and quantitative image analysis for pharma, biotech, and research organizations. Comparable in delivering automated quantitative tissue analysis for preclinical drug development workflows.
• TissueGnostics: Provider of automated tissue imaging and analysis solutions combining microscopy, image analysis software, and services. Comparable in combining imaging instrumentation with quantitative analysis for preclinical research.
• Visiopharm: Digital pathology AI software and image analysis services provider for pharma and research. Comparable in AI-driven quantitative image analysis applied to preclinical/clinical tissue samples.

Direct peers

• Flagship Biosciences: Digital pathology and tissue image analysis services for preclinical and clinical research. Directly comparable in offering quantitative histology, AI-driven image analysis, and pharmaceutical R&D deliverables.
• ImaBiotech: Preclinical molecular imaging CRO offering advanced 3D imaging (including MSOT/LSFM-style modalities) and quantitative analysis for pharma/biotech. Directly comparable as a specialized imaging services firm serving the same drug development customers.
• Biocellvia: Preclinical imaging and image analysis services provider specializing in 3D tissue imaging and quantitative histology. Closely aligned in technology stack (3D imaging + biology expertise) and B2B pharma/biotech services model.

Broad incumbents

• Charles River Laboratories: Large global preclinical CRO offering comprehensive drug discovery and safety assessment services, including histology and imaging capabilities. Overlaps in serving pharma/biotech preclinical needs, but as part of a vastly broader portfolio.
• PerkinElmer: Major life science and diagnostics instrumentation vendor with significant preclinical imaging product and services portfolio (e.g., IVIS, Opera). Comparable as an incumbent offering imaging instrumentation and services across the preclinical market.
• Eurofins Scientific: Global life science testing services group with significant preclinical and biopharma service offerings including imaging-adjacent capabilities. Comparable as a broad life-sciences services incumbent; not specialized in 3D imaging.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/imactiv-3d
• Xx.com/Imactiv3D

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imactiv-3D